武汉华康世纪洁净科技股份有限公司 独立董事述职报告 武汉华康世纪洁净科技股份有限公司 2024年度独立董事述职报告 各位股东及股东代理人： 本人作为武汉华康世纪洁净科技股份有限公司(以下简称"公司")的独立 董事、第二届董事会审计委员会召集人、第二届董事会薪酬与考核委员会委员， 严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和 国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办法》《武汉 华康世纪洁净科技股份有限公司章程》（以下简称"《公司章程》"）等相关 法律法规和规章制度的规定和要求，在2024年的工作中，忠实勤勉、恪尽职守， 积极出席各次董事会和股东大会，认真审议董事会各项议案，对公司相关事项发 表了独立、客观、专业的意见，切实维护了公司和股东尤其是中小股东的利益。 现将2024年度任职期间本人履行独立董事职责的情况向各位股东及股东代理人汇 报如下： 一、独立董事的基本情况 本人余亮，1976年12月出生，中国国籍，无境外永久居留权。2000年6月至 2001年7月，在武汉正浩会计师事务所，任项目经理；2001年8月至2004年7月，在 湖北中信会计师事务有限责任公司， ...

武汉华康世纪洁净科技股份有限公司 独立董事述职报告 武汉华康世纪洁净科技股份有限公司 2024年度独立董事述职报告 各位股东及股东代理人： 本人作为武汉华康世纪洁净科技股份有限公司(以下简称"公司")的独立 董事、第二届董事会提名委员会召集人、第二届董事会审计委员会委员，严格按照 《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券 法》（以下简称"《证券法》"）《上市公司独立董事管理办法》《武汉华康世 纪洁净科技股份有限公司章程》（以下简称"《公司章程》"）等相关法律法 规和规章制度的规定和要求，在2024年的工作中，忠实勤勉、恪尽职守，积极出 席各次董事会和股东大会，认真审议董事会各项议案，对公司相关事项发表了独 立、客观、专业的意见，切实维护了公司和股东尤其是中小股东的利益。现将 2024年度任职期间本人履行独立董事职责的情况向各位股东及股东代理人汇报如 下： 一、独立董事的基本情况 本人齐亮，1973年2月出生，中国国籍，无境外永久居留权。1997年至2021年， 在武汉乾坤律师事务所，担任律师；2001年至2018年，在湖北中和信律师事务所， 担任律师；2018年至2024年12月 ...

Financial Performance - The company's revenue for Q1 2025 was ¥295,271,024.99, representing a 28.54% increase compared to ¥229,705,391.58 in the same period last year[5]. - The net loss attributable to shareholders decreased by 9.72% to ¥-28,954,967.04 from ¥-32,071,670.93 year-on-year[5]. - The net profit excluding non-recurring items improved by 10.20%, amounting to ¥-29,990,803.71 compared to ¥-33,396,511.35 in the previous year[5]. - Basic and diluted earnings per share increased by 10.00% to ¥-0.27 from ¥-0.30 year-on-year[5]. - Net profit for the current period was -¥28,035,877.68, an improvement from -¥32,071,670.93 in the previous period, indicating a reduction in losses[20]. - Basic and diluted earnings per share were both -¥0.27, compared to -¥0.30 in the previous period[21]. Cash Flow and Assets - Cash flow from operating activities showed a decline of 28.30%, totaling ¥-192,510,065.52 compared to ¥-150,043,637.68 in the same period last year[5]. - Cash flow from operating activities showed a net outflow of -¥192,510,065.52, worsening from -¥150,043,637.68 in the previous period[22]. - Cash flow from investing activities resulted in a net outflow of -¥20,495,165.43, compared to -¥61,453,823.42 in the previous period, indicating reduced investment losses[23]. - Cash flow from financing activities recorded a net outflow of -¥2,081,893.05, a significant decrease from a net inflow of ¥165,475,678.21 in the previous period[23]. - The ending cash and cash equivalents balance was ¥730,221,634.91, up from ¥126,526,729.46 in the previous period[23]. - The company's cash and cash equivalents decreased from approximately 1.05 billion RMB to about 821.24 million RMB, reflecting a decline of around 21.6%[15][17]. - As of March 31, 2025, the company's total assets amounted to approximately 3.96 billion RMB, a decrease from 4.23 billion RMB at the beginning of the period[15][17]. - Total assets decreased by 6.37% to ¥3,957,324,709.16 from ¥4,226,342,757.17 at the end of the previous year[5]. Shareholder Equity and Liabilities - Shareholder equity attributable to the parent company decreased by 2.28% to ¥1,757,654,235.78 from ¥1,798,630,395.33 at the end of the previous year[5]. - Total current liabilities decreased from approximately 1.49 billion RMB to about 1.23 billion RMB, a decline of around 17.8%[16][17]. - The company's total equity decreased from approximately 1.80 billion RMB to about 1.78 billion RMB, a reduction of about 0.8%[17]. Orders and Operational Efficiency - The company reported an increase in orders due to the growth of sales and technical support personnel, indicating a positive trend in order backlog and new orders[8]. - The company is implementing comprehensive budgeting, process reforms, and personnel qualification assessments to enhance efficiency and reduce costs[8]. Research and Development - Research and development expenses increased to ¥21,405,242.23, up from ¥16,462,194.83 in the previous period, reflecting a focus on innovation[19]. Convertible Bonds - The company issued 7.5 million convertible bonds with a total value of 750 million RMB, set to be traded on the Shenzhen Stock Exchange starting January 9, 2025[12][13]. - The company plans to prioritize the issuance of convertible bonds to existing shareholders before offering any remaining bonds to the public[12].

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.71 billion, representing a 6.64% increase compared to ¥1.60 billion in 2023[16]. - The net profit attributable to shareholders decreased by 37.75% to approximately ¥66.81 million in 2024, down from ¥107.33 million in 2023[16]. - The net profit after deducting non-recurring gains and losses was approximately ¥57.68 million, a decrease of 36.51% from ¥90.84 million in the previous year[16]. - Basic earnings per share decreased by 38.24% to ¥0.63 in 2024, down from ¥1.02 in 2023[16]. - Total assets increased by 46.22% to approximately ¥4.23 billion at the end of 2024, compared to ¥2.89 billion at the end of 2023[16]. - The net assets attributable to shareholders increased by 2.55% to approximately ¥1.80 billion at the end of 2024, compared to ¥1.75 billion at the end of 2023[16]. - The company achieved operating revenue of 1,707.83 million yuan, a year-on-year increase of 6.64%[46]. - The net profit attributable to shareholders decreased by 37.75% to 66.81 million yuan, while the net profit after deducting non-recurring gains and losses fell by 36.51% to 57.68 million yuan[46]. - The company has a backlog of orders amounting to 2.753 billion yuan, with 2.07 billion yuan from medical specialty orders and 393 million yuan from laboratory orders[46]. Cash Flow and Financial Management - The net cash flow from operating activities improved significantly to approximately ¥147.56 million, compared to a negative cash flow of ¥187.36 million in 2023, marking a 178.76% increase[16]. - The company has a net cash flow from operating activities of 147.56 million yuan, a significant increase of 178.76%[46]. - Operating cash inflow increased by 15.77% to ¥1,717,885,727.63 in 2024, while operating cash outflow decreased by 6.04% to ¥1,570,323,385.39, resulting in a net cash flow from operating activities of ¥147,562,342.24, a significant improvement of 178.76%[116]. - Net cash flow from financing activities rose by 105.05% to ¥763,050,861.29, primarily due to funds raised from issuing convertible bonds[117]. - The company's cash and cash equivalents increased significantly by 1,872.44% to ¥77,276,020, driven by the issuance of convertible bonds[117]. Market and Industry Trends - The domestic cleanroom market is projected to exceed $500 billion by 2032, with a compound annual growth rate (CAGR) of over 7% from 2023 to 2032[32]. - The cleanroom industry is experiencing a shift towards high-end development, driven by the increasing complexity and demand for cleanroom technology[29]. - The global nuclear medicine market is projected to reach $23 billion by 2028, with a 18.7% annual growth in China's nuclear medicine diagnosis volume[109]. Research and Development - The company has filed for 23 invention patents and 17 utility model patents, successfully obtaining 8 invention patents and 9 utility model patents during the year[50]. - The company has filed 64 new patent applications in the current period, with 36 granted, bringing the total to 329 applications and 253 granted patents[90]. - R&D investment amounted to ¥64,496,790 in 2024, a decrease of 24.36% from ¥85,227,776.77 in 2023, with the ratio of R&D investment to operating revenue falling from 5.32% to 3.78%[114]. Strategic Initiatives - The company is focusing on optimizing medical purification system solutions to enhance service efficiency and resource utilization in healthcare institutions[35]. - The company has established an electronic cleanroom division to focus on semiconductor and high-tech industry cleanroom solutions[48]. - The company has established an innovation development research institute to focus on key core technology breakthroughs and address industry challenges[84]. - The company aims to enhance service efficiency by over 40% through digitalization of service processes and preventive maintenance systems[109]. - The company is transitioning towards smart operation service providers, leveraging technology to enhance customer engagement and market competitiveness[109]. Governance and Management - The company has established a comprehensive internal control system to manage risks and ensure normal operations[176]. - The board of directors operates independently, with specialized committees providing professional advice to enhance decision-making efficiency[171]. - The company maintains a clear separation from its controlling shareholder in terms of assets, personnel, and operations, ensuring independent business capabilities[170]. - The company has a strong governance structure with independent board members and management, ensuring no interference from controlling shareholders in personnel decisions[182]. Risks and Challenges - The company faces a significant risk of large accounts receivable and potential bad debt losses due to long payment cycles associated with its medical purification system integration business, with receivables typically taking about 2 years to collect[157]. - The cash flow risk is heightened by the capital-intensive nature of the purification system integration business, which requires substantial upfront funding, leading to potential negative cash flow if clients delay payments[159]. - The company is at risk of declining gross margins due to increased market competition and rising costs, prompting a focus on refined management and product innovation to enhance competitiveness[161].

证券代码：301235 证券简称：华康洁净 公告编号：2025-031 转债代码：123251 转债简称：华医转债 一、中标项目基本情况 1、建设规模：本项目总建筑面积约 8,000.00 平方米。主楼地上 9 层，无地 下室；附楼地上 3 层，无地下室。室外场地改造面积约 4,000.00 平方米。 2、建设地点：武汉大学信息学部 3、中标范围：建筑安装工程的施工图设计、施工以及设备采购。 4、中标价：107,821,822.00 元 5、工期：540 日历天 武汉华康世纪洁净科技股份有限公司 关于收到中标通知书的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 | | --- | | 载、误导性陈述或重大遗漏。 | 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 4 月 3 日在创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于 项目预中标的提示性公告》（公告编号：2025-027）。近日，公司收到招标代理 机构中创恒梦工程咨询有限公司发出的《中标通知书》，确认公司与中南建筑设 计院股份有限公司组成的联合体（以下简称"联合体 ...

证券代码：301235 证券简称：华康洁净 公告编号：2025-030 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于收到中标通知书的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 | | --- | | 载、误导性陈述或重大遗漏。 | 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 3 月 20 日在创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于 项目预中标的提示性公告》（公告编号：2025-024）。近日，公司收到招标单位 中江县人民医院发出的《中标通知书》，确认公司为"中江县人民医院改扩建项 目医疗专项工程、中江县人民医院感染性疾病楼建设项目医疗专项工程"项目的 中标供应商。现将中标项目的主要内容公告如下： 2、法定代表人：王铸 3、开办资金：64,092.44 万元 一、中标项目基本情况 1、建设规模：包含 1 号楼医技楼放射科、检验科、内镜中心、病理科、DS A、输血科、供应室、牙科、手术室，2 号楼住院楼放射科(DSA、CT)、CCU、ICU、 HASU、NCU、RICU 静 ...

029 转债代码:123251 转债简称:华医转债 证券代码：301235 证券简称：华康洁净 公告编号：2025- 武汉华康世纪洁净科技股份有限公司 关于回购公司股份比例达到 2%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2024 年 11 月 5 日召开第二届董事会第十九次会议、第二届监事会第十八次会议，于 2024 年 11 月 21 日召开 2024 年第五次临时股东大会，审议通过《关于回购公司股份方 案的议案》，公司将使用自有资金及自筹资金（含回购专项贷款资金）以集中竞 价交易方式回购部分公司已在境内发行上市人民币普通股（A 股）股票，用于实 施员工持股计划或股权激励计划。 本次回购股份的资金总额不低于人民币 5,000 万元（含），不超过人民币 7,000 万元（含），回购股份的价格不超过 28.00 元/股（含本数）。具体回购数 量以回购期限届满时实际回购的股份数量为准。本次回购的实施期限为自公司股 东大会审议通过回购方案之日起 12 个月内。具体内容详见公司于 2024 ...

028 转债代码:123251 转债简称:华医转债 证券代码：301235 证券简称：华康洁净 公告编号：2025- 武汉华康世纪洁净科技股份有限公司 关于回购公司股份比例达到 1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2024 年 11 月 5 日召开第二届董事会第十九次会议、第二届监事会第十八次会议，于 2024 年 11 月 21 日召开 2024 年第五次临时股东大会，审议通过《关于回购公司股份方 案的议案》，公司将使用自有资金及自筹资金（含回购专项贷款资金）以集中竞 价交易方式回购部分公司已在境内发行上市人民币普通股（A 股）股票，用于实 施员工持股计划或股权激励计划。 本次回购股份的资金总额不低于人民币 5,000 万元（含），不超过人民币 7,000 万元（含），回购股份的价格不超过 28.00 元/股（含本数）。具体回购数 量以回购期限届满时实际回购的股份数量为准。本次回购的实施期限为自公司股 东大会审议通过回购方案之日起 12 个月内。具体内容详见公司于 2024 ...

| | | 4月3日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 销售数据 | 中通客车 | 1-3月累计销售量2766辆 同比增长10.02% | | | 广汽集团 | 3月销量为17.39万辆,同比下降3.01% | | 项目投资 | 顺控发展 | 拟投建顺德区资源循环利用中心(北滘)项目 | | 合同中标 | 华康洁净 | 联合体预中标"武汉大学细胞资源库项目维修改造工程设计施工总承包" | | 业绩披露 | 东兴证券 | 2024年净利润15.44亿元,同比增长88.39% | | | 利尔化学 | 一季度净利润预增203.08%-223.98% | | 股权转让 | 圣农发展 | 拟收购太阳谷54%股权 | | 回购 | 三一重工 | 拟斥资10亿元 20亿元回购股份 | | 增减持 | 嘉受服饰 | 深圳架桥、天津架桥拟合计减持不超3%股份 | | | 濮耐股份 | 实际控制人刘百宽家族部分成员拟合计减持不超0.993%股份 | | 其他 | 矩光科技 | 获得某欧洲知名汽车 Tierl 客户两个项目定点 | | | 东安动力 | 2025年一 ...

证券代码：301235 证券简称：华康洁净 公告编号：2025-027 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于项目预中标的提示性公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 | | --- | | 载、误导性陈述或重大遗漏。 | 特别提示：本项目为联合体中标，截至本公告披露之日，项目处于中标候选 人公示阶段，其中标、签约等后续工作尚具有一定不确定性，敬请广大投资者注 意投资风险。武汉华康世纪洁净科技股份有限公司（以下简称"公司"）将根据 相关事项后续进展情况履行相应的信息披露义务。 公司与中南建筑设计院股份有限公司组成的联合体（以下简称"联合体"） 于近日参与了"武汉大学细胞资源库项目维修改造工程设计施工总承包"项目的 投标，招标单位为武汉大学。2025 年 4 月 3 日，湖北省电子招投标交易平台（h ttps://www.hbbidcloud.cn/hubei/）发布了招标评标结果公示。现将具体预中 标情况提示如下： 一、预中标项目概况 1、招标单位名称：武汉大学 2、招标代理机构名称：中创恒梦工程咨询有限公司 3、工程名称：武 ...